ArticleCancer medicine2021

225Ac-labeled CD33-targeting antibody reverses resistance to Bcl-2 inhibitor venetoclax in acute myeloid leukemia models.

Ravendra Garg et al.PubMed ↗Full text ↗Publisher ↗

No numbers read from the abstract.